ArticleTherapeutic advances in medical oncology2022

Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial.

Ciqiu Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.